During the corresponding time, Bionano Genomics Inc recorded a revenue increase by 21.36 % year on year, sequentially revenue grew by 22.19 %. While revenue at the Bionano Genomics Inc 's corporate clients
Bionano Genomics Inc's Comment on Sales, Marketing and Customers
The company provides products and services for genomic analysis, focusing on optical genome mapping (OGM) technology and related offerings such as the Stratys™ system and VIA™ software. It targets markets that utilize OGM as an alternative to traditional cytogenetics and seeks to increase OGM adoption through research, presentations, and publications. The company plans to expand its commercial organization to address both existing and new markets and to introduce new products and applications for its technology platforms. It considers market acceptance, growth potential, and competitive positioning as key factors. The company also relies on third-party contract sales organizations, suppliers, manufacturers, research partners, and strategic collaborations to support its operations.
Optical Genome Mapping Outperforms Traditional Cytogenetic Assays in Bone and Soft Tissue Tumor Analysis: A Study by Johns Hopkins University Recent advancements in genetic analysis techniques have brought transformative potential to the field of oncology. The emergence of Optical Genome Mapping (OGM) represents a breakthrough capable of surpassing conventional cytogenetic methods in specific applications. A recent publication in Modern Pathology by researchers from the Johns Hopkins University School of Medicine provides compelling evidence supporting OGM s superior performance in analyzing bone and soft tissue tumors, compared to traditional cytogenetic assays. Study OverviewThe study conducted by the J...
In the ever-evolving landscape of cancer research, Bionano Genomics, Inc. has made promising strides with their groundbreaking optical genome mapping (OGM) technology. The company s recent publication showcases the utility of OGM in multiple myeloma (MM), solid tumor cancers, and hereditary breast and ovarian cancer (HBOC) syndrome. These studies have not only highlighted the effectiveness of OGM in detecting genetic aberrations, structural variants (SVs), and chromothripsis events, but have also shed light on their potential implications for prognosis, tumor progression, and chemotherapy resistance.The multi-site study conducted in multiple myeloma examined the efficacy of OGM compared to traditional cytoge...
In a significant breakthrough in cancer research, Bionano Genomics Inc. has publicized the results of a study showcasing the efficacy of Optical Genome Mapping (OGM) in the detection of high-resolution structural variations in leukemia samples. These findings were subsequently substantiated using Cas9-Directed Nanopore Sequencing an advanced technique that epitomizes the leading edge of genomics.The successful use of Optical Genome Mapping, which involves the comprehensive review of genomes to spot variations or alterations, illustrates a pivotal step ahead in the realm of genomics. It will be especially beneficial in enhancing cancer s diagnostic precision and assisting in targeted treatment options given...
Genomic analysis plays a crucial role in understanding various diseases, particularly in pediatric oncology. Recent studies have highlighted the limitations of conventional techniques such as whole genome sequencing (WGS) in accurately detecting structural variants (SVs). However, a breakthrough publication by Bionano Genomics presents a compelling case for the utilization of optical genome mapping (OGM) as a complementary tool to identify an extensive range of SVs, including gene fusions, that were missed by WGS. This article aims to outline the findings and implications of this study on improving diagnostics and treatment outcomes in pediatric leukemia.The Study:Researchers at Bionano Genomics, by integrat...
In a bid to improve the diagnosis and understanding of solid tumor cancers, scientific researchers have reaffirmed the remarkable potential of optical genome mapping (OGM) to identify genetic aberrations that were previously missed by classical cytogenetic techniques. Bionano Genomics, an innovative life sciences company, recently published the results of a peer-reviewed study showcasing the groundbreaking impact of OGM in detecting previously elusive genetic anomalies in sarcoma samples. The findings shed new light on the diagnostic potential of OGM and its ability to revolutionize personalized medicine.The Study s and Methodology:The study aimed to assess the effectiveness of OGM in comparison to classica...
Bionano Genomics Inc’s Comment on Sales, Marketing and Customers
The company provides products and services for genomic analysis, focusing on optical genome mapping (OGM) technology and related offerings such as the Stratys™ system and VIA™ software. It targets markets that utilize OGM as an alternative to traditional cytogenetics and seeks to increase OGM adoption through research, presentations, and publications. The company plans to expand its commercial organization to address both existing and new markets and to introduce new products and applications for its technology platforms. It considers market acceptance, growth potential, and competitive positioning as key factors. The company also relies on third-party contract sales organizations, suppliers, manufacturers, research partners, and strategic collaborations to support its operations.
Sources:
Bionano Genomics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Bionano Genomics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Bionano Genomics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
168.73 %